CAMBRIDGE, MA - July 19, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of first-in-class RNA-based therapeutics, announced today that its lead therapeutic drug candidate for the Marburg virus, AVI-7288, demonstrated up to 100% survival in a non-human primate (NHP) study exploring the drug's effect when treatment is delayed to various time points post-infection.